Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Jeet will be a trusted partner in cardiovascular care
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
